JPS52136172A - Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect - Google Patents

Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect

Info

Publication number
JPS52136172A
JPS52136172A JP5418677A JP5418677A JPS52136172A JP S52136172 A JPS52136172 A JP S52136172A JP 5418677 A JP5418677 A JP 5418677A JP 5418677 A JP5418677 A JP 5418677A JP S52136172 A JPS52136172 A JP S52136172A
Authority
JP
Japan
Prior art keywords
rulibeline
polypeptide
medical
preparation
synergistic effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP5418677A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6113480B2 (OSRAM
Inventor
Suwaruupu Doutsuta Anando
Jiyon Arubaato Fuaa Baarinton
Buraian Jiyairuzu Maikuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of JPS52136172A publication Critical patent/JPS52136172A/ja
Publication of JPS6113480B2 publication Critical patent/JPS6113480B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
JP5418677A 1976-05-11 1977-05-11 Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect Granted JPS52136172A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Publications (2)

Publication Number Publication Date
JPS52136172A true JPS52136172A (en) 1977-11-14
JPS6113480B2 JPS6113480B2 (OSRAM) 1986-04-14

Family

ID=10127509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5418677A Granted JPS52136172A (en) 1976-05-11 1977-05-11 Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect

Country Status (27)

Country Link
US (1) US4100274A (OSRAM)
JP (1) JPS52136172A (OSRAM)
AT (2) AT379400B (OSRAM)
AU (1) AU508025B2 (OSRAM)
BE (1) BE854467A (OSRAM)
BG (1) BG60740B2 (OSRAM)
CA (1) CA1101844A (OSRAM)
CH (2) CH627151A5 (OSRAM)
CS (1) CS199673B2 (OSRAM)
DD (1) DD136738A5 (OSRAM)
DE (1) DE2720245C2 (OSRAM)
DK (1) DK149596C (OSRAM)
ES (1) ES458691A1 (OSRAM)
FI (1) FI64139C (OSRAM)
FR (1) FR2351092A1 (OSRAM)
GB (1) GB1524747A (OSRAM)
HU (1) HU179990B (OSRAM)
IE (1) IE44426B1 (OSRAM)
IL (1) IL52014A (OSRAM)
NL (2) NL191793C (OSRAM)
NO (2) NO147304C (OSRAM)
NZ (1) NZ183931A (OSRAM)
PL (2) PL104362B1 (OSRAM)
SE (2) SE437837B (OSRAM)
SU (1) SU910116A3 (OSRAM)
YU (1) YU40672B (OSRAM)
ZA (1) ZA772433B (OSRAM)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55164663A (en) * 1979-06-11 1980-12-22 Syntex Inc Nonapeptide and decapeptide derivatives of progesterone release hormone and its manufacture
EP0779072A1 (en) 1995-12-15 1997-06-18 Takeda Chemical Industries, Ltd. Production of microspheres
EP0781548A2 (en) 1995-12-15 1997-07-02 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
WO2003041739A1 (fr) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Agents anticancer
JP2009227687A (ja) * 2004-06-25 2009-10-08 Takeda Chem Ind Ltd メタスチン誘導体およびその用途

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
JPH0284272U (OSRAM) * 1988-12-20 1990-06-29
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
NZ244499A (en) * 1989-03-10 1999-05-28 Endorecherche Inc Treating breast or endometrial cancer with antiestrogen plus one of an androgen, a progestin and an inhibitor of sex steroid formation or secretion of prolactin, growth hormone or acth
DE69032648T2 (de) * 1989-07-07 1999-04-08 Endorecherche Inc., Ste-Foy, Quebec Androgenderivate zur Hemming der Aktivität der Sexualsteroide
DE69034035T2 (de) * 1989-07-07 2004-01-22 Endorecherche Inc., Ste-Foy Methode zur behandlung androgenbedingter krankheiten
GB9112859D0 (en) * 1991-06-14 1991-07-31 Ici Plc Peptide process
AU4258493A (en) * 1992-05-21 1993-12-13 Endorecherche Inc. Inhibitors of testosterone 5alpha-reductase activity
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
EP1008656A4 (en) 1996-06-13 2000-09-20 Itoham Foods Inc METHOD FOR PRODUCING LH-RH DERIVATIVES
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
PT2269603E (pt) 2001-02-19 2015-09-09 Novartis Ag Tratamento de tumores da mama com um derivado de rapamicina em combinação com exemestano
PT1392313E (pt) 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
WO2005097791A1 (en) 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
KR101346886B1 (ko) 2005-01-21 2014-01-02 아스텍스 테라퓨틱스 리미티드 제약 화합물
EP2119725A1 (en) * 2005-05-03 2009-11-18 Novetide Ltd. Methods for the production of leuprolide
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
KR20080054417A (ko) 2005-09-27 2008-06-17 노파르티스 아게 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
EP2026800A1 (en) 2006-05-09 2009-02-25 Novartis AG Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
EP2117521B1 (en) 2006-11-03 2012-06-27 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
EP2067471B1 (en) * 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
EP2260020B1 (en) 2008-03-26 2014-07-23 Novartis AG Hydroxamate-based inhibitors of deacetylases b
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP2012510442A (ja) * 2008-11-28 2012-05-10 ノバルティス アーゲー Ｈｓｐ９０阻害剤の組合せ
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
UA105794C2 (uk) 2009-06-26 2014-06-25 Новартіс Аг 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
EA201200321A1 (ru) 2009-08-26 2012-09-28 Новартис Аг Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
EA201200471A1 (ru) 2009-09-10 2012-10-30 Новартис Аг Простые эфирные производные бициклических гетероарилов
JP5466767B2 (ja) 2009-11-04 2014-04-09 ノバルティス アーゲー Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
US20120289501A1 (en) 2009-11-25 2012-11-15 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
ES2484171T3 (es) 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
WO2011156908A1 (en) 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
EP2582680A1 (en) 2010-06-17 2013-04-24 Novartis AG Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
EP2709991B1 (en) 2011-05-16 2020-09-02 Genzyme Corporation Use of cxcr4 antagonists for treating WHIM syndrome, myelokathexis, neutropenia and lymphocytopenia
MX2013014398A (es) 2011-06-09 2014-03-21 Novartis Ag Derivados de sulfonamida heterociclicos.
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
PH12013502524A1 (en) 2011-06-27 2014-01-27 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
PE20141598A1 (es) 2011-12-22 2014-11-14 Novartis Ag Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355619A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
WO2013188763A1 (en) 2012-06-15 2013-12-19 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
EP2882747B1 (en) 2012-08-13 2016-04-27 Novartis AG Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk)
MX2015003959A (es) 2012-10-02 2015-11-16 Epitherapeutics Aps Inhibidores de histona demetilasas.
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
ES2670864T3 (es) 2013-02-27 2018-06-01 Gilead Sciences, Inc. Inhibidores de histonas desmetilasas
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
CA2918938C (en) 2013-09-22 2021-05-18 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
RU2020121929A (ru) 2014-01-15 2020-07-13 Новартис Аг Фармацевтические комбинации
WO2015148868A1 (en) 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AR099890A1 (es) 2014-03-31 2016-08-24 Epitherapeutics Aps Inhibidores de histona demetilasas
WO2015153345A1 (en) 2014-04-03 2015-10-08 Invictus Oncology Pvt. Ltd. Supramolecular combinatorial therapeutics
MX2017002451A (es) 2014-08-27 2017-05-23 Gilead Sciences Inc Compuestos y metodos para inhibir histona desmetilasas.
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
JP7258561B2 (ja) 2016-07-06 2023-04-17 オリエント ファーマ シーオー．，エルティーディー． 薬物組成物、バリヤー層及び薬物層を有している経口投与形態
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
WO2019119486A1 (zh) 2017-12-21 2019-06-27 中国科学院合肥物质科学研究院 一类嘧啶类衍生物激酶抑制剂
WO2019143874A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CA3155594C (en) 2019-09-26 2025-06-17 S I S Shulov Innovative Science Ltd Topical anti-aging compositions containing a tetrapeptide
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
JPS50142563A (OSRAM) * 1974-04-26 1975-11-17
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US3971737A (en) * 1975-03-24 1976-07-27 American Home Products Corporation [2-Methyl-Ala6 ]LRH
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55164663A (en) * 1979-06-11 1980-12-22 Syntex Inc Nonapeptide and decapeptide derivatives of progesterone release hormone and its manufacture
JPS63264498A (ja) * 1979-06-11 1988-11-01 シンテックス（ユー．エス．エー．）インコーポレイティド 黄体形成ホルモン放出ホルモンのノナペプチド及びデカペプチド誘導体
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
EP0779072A1 (en) 1995-12-15 1997-06-18 Takeda Chemical Industries, Ltd. Production of microspheres
EP0781548A2 (en) 1995-12-15 1997-07-02 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection
WO2003041739A1 (fr) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Agents anticancer
JP2009227687A (ja) * 2004-06-25 2009-10-08 Takeda Chem Ind Ltd メタスチン誘導体およびその用途

Also Published As

Publication number Publication date
FR2351092B1 (OSRAM) 1980-02-22
DK149596B (da) 1986-08-04
IL52014A (en) 1979-11-30
NO147304C (no) 1983-03-16
CS199673B2 (en) 1980-07-31
NL191793B (nl) 1996-04-01
FI64139C (fi) 1983-10-10
NO149586B (no) 1984-02-06
HU179990B (en) 1983-01-28
FR2351092A1 (fr) 1977-12-09
FI771480A7 (OSRAM) 1977-11-12
BG60740B2 (bg) 1996-01-31
CH627151A5 (OSRAM) 1981-12-31
IE44426L (en) 1977-11-11
ATA335877A (de) 1985-05-15
SE7705432L (sv) 1977-11-12
NL970002I1 (nl) 1997-03-03
ATA217979A (de) 1981-06-15
NO822984L (no) 1977-11-14
ES458691A1 (es) 1978-08-16
NL191793C (nl) 1996-08-02
SU910116A3 (ru) 1982-02-28
AU2468177A (en) 1978-11-02
CA1101844A (en) 1981-05-26
IL52014A0 (en) 1977-07-31
IE44426B1 (en) 1981-11-18
NL7705130A (nl) 1977-11-15
YU117277A (en) 1983-02-28
AU508025B2 (en) 1980-03-06
SE8007763L (sv) 1980-11-05
JPS6113480B2 (OSRAM) 1986-04-14
DE2720245C2 (de) 1986-09-25
GB1524747A (en) 1978-09-13
CH629475A5 (de) 1982-04-30
SE437837B (sv) 1985-03-18
AT379400B (de) 1985-12-27
NO149586C (no) 1984-05-16
US4100274A (en) 1978-07-11
DK207977A (da) 1977-11-12
FI64139B (fi) 1983-06-30
DD136738A5 (de) 1979-07-25
DK149596C (da) 1987-01-05
NL970002I2 (nl) 1997-05-01
ZA772433B (en) 1978-03-29
NO147304B (no) 1982-12-06
NO771644L (no) 1977-11-14
BE854467A (fr) 1977-11-10
AT365562B (de) 1982-01-25
PL104362B1 (pl) 1979-08-31
SE437993B (sv) 1985-03-25
PL197889A1 (pl) 1978-02-13
YU40672B (en) 1986-04-30
PL108860B1 (en) 1980-05-31
NZ183931A (en) 1979-03-16
DE2720245A1 (de) 1977-11-24

Similar Documents

Publication Publication Date Title
JPS52136172A (en) Polypeptide* its preparation and medical and veterinary compositions having rulibeline synergistic effect
NZ188626A (en) Acylanilides and pharmaceutical and veterinary compositions
JPS5318557A (en) Novel aminoalkylfuran derivatives* their preparation and medical composition containing same
IL51660A0 (en) Hentriakontapeptides their preparation and pharmaceutical compositions containing them
JPS51115910A (en) Gradually releaseetype medical composition and its preparation
NZ185986A (en) 2-oxa-bicyclic prostag-landins and pharmaceutical compositions
NZ188173A (en) 7-arylmalonamido-7 a-methoxy-3-(optionally alkylated-thiadiazol-2-yl) thiomethyl-1-oxadethiacephalosporins preparation and pharmaceutical and veterinary compositions
NZ183551A (en) Aminochromanols and pharmaceutical compositions containingthem
NZ185358A (en) Spiro-hydantoins and pharmaceutical compositions
ZA752957B (en) Insecticidal compositions and use
JPS5297921A (en) Aralkylaniline derivative* preparation thereof and medical composition containing same
NZ183134A (en) I-i-(3-aryloxy-2-hydroxypropyl)-4-piperidyl-3-aryl-imid-azolidin or hexahydropyrimidin-2-ones; and pharmaceutical compositions
NZ184428A (en) N-acyl-l-alanyl-aminoacyl-amides untermediates and pharmaceutical compositions
JPS5386038A (en) Pharmaceutical composition for animal and application
JPS549282A (en) Novel aminopiperidines*its preparation*and medical compositions
NZ184766A (en) Alkylphenyl ethers and thioethers and pharmaceutical compositions
JPS5323938A (en) Peptide having psychoopharmacologcal activity* its derivative* composition containing same and preparation thereof
JPS5416402A (en) Peptide and medical composition containing same
NZ184912A (en) 2-phenylamino-imidazolines and pharmaceutical compositions
NZ184263A (en) N-(amino-alkyl-amino)-benzamides and pharmaceutical compositions
JPS5346972A (en) Polypeptide* its preparation and pharmaceutical* veterinary composition having rulibeline antagonism
NZ184735A (en) Peptides and pharmaceutical compositions
JPS52102279A (en) And its preparation and medical composition containing same
NZ183549A (en) Amidinopencillanoyloxy-alkyl-amoxycillinates and pharmaceutical compositions
ZA77271B (en) Therapeutic compositions and use thereof